240 related articles for article (PubMed ID: 16705684)
1. Association between amantadine and the onset of dementia in Parkinson's disease.
Inzelberg R; Bonuccelli U; Schechtman E; Miniowich A; Strugatsky R; Ceravolo R; Logi C; Rossi C; Klein C; Rabey JM
Mov Disord; 2006 Sep; 21(9):1375-9. PubMed ID: 16705684
[TBL] [Abstract][Full Text] [Related]
2. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
3. [The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Zhe X; Qu QM; Wang RL; Cao HM; Qiao J; Guo F
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1065-8. PubMed ID: 20193391
[TBL] [Abstract][Full Text] [Related]
4. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease.
Meral H; Aydemir T; Ozer F; Ozturk O; Ozben S; Erol C; Cetin S; Hanoglu L; Ozkayran T; Yilsen M
Clin Neurol Neurosurg; 2007 Dec; 109(10):862-7. PubMed ID: 17913346
[TBL] [Abstract][Full Text] [Related]
5. Amantadine in Parkinson's disease: pro and contra.
Greulich W; Fenger E
J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
[TBL] [Abstract][Full Text] [Related]
6. [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure].
Lökk J
Lakartidningen; 2004 Jun; 101(23):2003-6. PubMed ID: 15232837
[TBL] [Abstract][Full Text] [Related]
7. [Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].
Malsch U; Bliesath H; Böther K; Ramm H; Lühmann R
Fortschr Neurol Psychiatr; 2001 Feb; 69(2):86-9. PubMed ID: 11253562
[TBL] [Abstract][Full Text] [Related]
8. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease.
Uitti RJ; Rajput AH; Ahlskog JE; Offord KP; Schroeder DR; Ho MM; Prasad M; Rajput A; Basran P
Neurology; 1996 Jun; 46(6):1551-6. PubMed ID: 8649547
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
10. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
Kubo S; Iwatake A; Ebihara N; Murakami A; Hattori N
Parkinsonism Relat Disord; 2008; 14(2):166-9. PubMed ID: 17509924
[TBL] [Abstract][Full Text] [Related]
11. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series.
Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A
Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995
[TBL] [Abstract][Full Text] [Related]
12. Dementia in Parkinson's disease: a post-mortem study in a population of brain donors.
Papapetropoulos S; Gonzalez J; Lieberman A; Villar JM; Mash DC
Int J Geriatr Psychiatry; 2005 May; 20(5):418-22. PubMed ID: 15852454
[TBL] [Abstract][Full Text] [Related]
13. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
Vale S
Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
[TBL] [Abstract][Full Text] [Related]
14. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
[TBL] [Abstract][Full Text] [Related]
15. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease.
Haugarvoll K; Aarsland D; Wentzel-Larsen T; Larsen JP
Acta Neurol Scand; 2005 Dec; 112(6):386-90. PubMed ID: 16281921
[TBL] [Abstract][Full Text] [Related]
16. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?
Papapetropoulos S; Lieberman A; Gonzalez J; Mash DC
Acta Neurol Scand; 2005 Jun; 111(6):353-9. PubMed ID: 15876335
[TBL] [Abstract][Full Text] [Related]
17. Smoking and cognitive function in Parkinson's disease.
Weisskopf MG; Grodstein F; Ascherio A
Mov Disord; 2007 Apr; 22(5):660-5. PubMed ID: 17266085
[TBL] [Abstract][Full Text] [Related]
18. Cognitive and behavioural impairment in Parkinson's disease.
Merims D; Freedman M
Int Rev Psychiatry; 2008 Aug; 20(4):364-73. PubMed ID: 18925485
[TBL] [Abstract][Full Text] [Related]
19. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.
Janvin CC; Larsen JP; Aarsland D; Hugdahl K
Mov Disord; 2006 Sep; 21(9):1343-9. PubMed ID: 16721732
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
